Psilocybin - PsyBio Therapeutics
Alternative Names: Biosynthetic psilocybin - PsyBio Therapeutics; PB-1818Latest Information Update: 28 Jun 2023
At a glance
- Originator PsyBio Therapeutics
- Class Analgesics; Anti-infectives; Anti-inflammatories; Antidepressants; Antineoplastics; Antipsychotics; Anxiolytics; Behavioural disorder therapies; Dimethylamines; Drug withdrawal therapies; Indoles; Mood stabilisers; Neuropsychotherapeutics; Organophosphorus compounds; Phytotherapies; Small molecules
- Mechanism of Action ATP-binding cassette transporter modulators; Serotonin 5-HT2 receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Depressive disorders
Most Recent Events
- 28 Jun 2023 No recent reports of development identified for phase-I development in Depressive disorders in USA
- 06 Dec 2022 PsyBio Therapeutics files four U.S. Patent Cooperation Treaty (PCT) patent applications related to advancements concerning production methodology, host strains and processes of production
- 11 Oct 2022 PsyBio Therapeutics plans a clinical trial for Mental disorders